Voyager Secures Geisinger Partnership

“Signing a health system of Geisinger’s caliber is a defining moment for VISTA,” said John Baum, chief strategy and marketing officer, Voyager. “Microgravity enables research that simply isn’t possible on Earth, and that opens real doors for cancer treatment, therapies for diseases and next-gen treatments at a scale the biopharma and life sciences world is paying close attention to. Geisinger has the clinical depth and scientific rigor to carry that research all the way to patient care, and their decision to collaborate with VISTA is a signal to the entire industry.”

Under the MOU, Voyager and Geisinger will pursue shared programs and seek external funding to support further technological development. Voyager and Geisinger will jointly pursue up to $1 million in external funding for research opportunities that leverage microgravity to advance clinical and biomedical initiatives. The agreement provides reserved research resources, tenant access, payload development support through Starlab and other commercial space infrastructure, and collaboration within the VISTA ecosystem. Focus areas span translational pathways for space-based drug development, remote patient monitoring and telehealth, next-generation cybersecurity health platforms, multi-omics and biological effects of spaceflight, and clinical trial opportunities uniquely enabled by microgravity.

VISTA is the first-of-its-kind U.S. science park dedicated to in-space research, manufacturing and services, anchored at The Ohio State University. Its network has expanded rapidly over the past year with universities and commercial tenants, with momentum building across domestic and international markets. With access to the International Space Station and future commercial space platforms, VISTA tenants can develop next-generation technologies and services across civil, commercial and national security markets. For more information, visit vistaspacepark.com.

Press assets available here.

About Voyager Technologies

Voyager Technologies is a defense technology and space solutions company that enables mission-ready systems that secure today and power what’s next for the U.S. and partner nations. From propulsion and energetics to advanced electronics, mission management and space exploration, Voyager delivers capabilities that protect national security, reinforce the industrial base and expand human presence beyond Earth. For more information visit: voyagertechnologies.com and follow on LinkedIn and X.

About Geisinger

Geisinger is among the nation’s leading providers of value-based care, serving 1.2 million people in rural and urban communities across central and northeastern Pennsylvania. Founded in 1915 by philanthropist Abigail Geisinger, the nonprofit system generates $9 billion in annual revenues across more than 130 care sites — including 10 hospital campuses — and Geisinger Health Plan, with 509,000+ enrollees in commercial and government plans. Geisinger College of Health Sciences educates more than 600 medical professionals annually and conducts more than 1,600 clinical research studies. With 28,000 employees, including 1,900 employed physicians and 5,400 registered nurses, Geisinger is among Pennsylvania’s largest employers with an estimated economic impact of $18 billion on the state’s economy. In 2024, Geisinger joined Risant Health, a nonprofit charitable organization created to expand and accelerate value-based care across the country. Learn more at geisinger.org or connect with us on Facebook, Instagram and LinkedIn.

Cautionary Statement Concerning Forward-Looking Statements:

This press release contains “forward-looking statements.” All statements, other than statements of historical fact, including those with respect to Voyager Technologies, Inc.’s (the “Company’s”) mission statement and growth strategy, are “forward-looking statements.” Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve many risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, the Company’s ability to sustain and generate growth, ability to generate a sustainable order rate for its products and services and develop new technologies to meet customer needs, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; and the ability to obtain necessary financing on acceptable terms or at all. Readers should not place any undue reliance on forward-looking statements since they involve these known and unknown uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716546294/en/

Voyager Media Contact
Nora Ellish,
The 10 Group USA for Voyager Technologies,
[email protected]

Geisinger Media Contact:
Chris Murphy,
Geisinger Health,
[email protected]

KEYWORDS: Ohio Colorado Pennsylvania United States North America

INDUSTRY KEYWORDS: Research Contracts Pharmaceutical Biometrics Technology Defense Health Technology Satellite Science Biotechnology Aerospace Health Manufacturing

MEDIA:

Logo